Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Hasbro, Inc. (HAS) Price & Performance

Abbott LaboratoriesTrade
Hasbro, Inc.Trade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Hasbro, Inc. — how do they compare? Abbott Laboratories trades at $110.04 (market cap $187.95B), while Hasbro, Inc. trades at $97.18 (market cap $13.33B). The key difference: Abbott Laboratories is far larger — about 14.1× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (2.96%). Which is the better fit depends on your goals.

ABTHAS
Market Cap
$187.95B$13.33B
Sector
HealthConsumer Cyclical
52-Week High
$136.62$105.88
52-Week Low
$82.57$70.95
Enterprise Value
$214.96B$15.52B
Dividend Yield
2.32%2.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $107.80, down slightly by 0.14% today. The stock shows a bullish technical signal with strong moving average support and a consensus analyst price target of $120.70. Recent earnings beat expectations in Q1 and Q2 2026, while revenue grew to $44.33 billion in 2025. The company secured a CE Mark for its Libre Duo glucose-ketone sensor, highlighting innovation in diabetes care.

The outlook remains positive given analyst consensus and recent product approvals, but risks include competitive pressures and macroeconomic volatility. Upside potential exists if earnings momentum continues, though valuation multiples are above industry averages, warranting caution on significant expansion.

Hasbro, Inc.

Hasbro (HAS) trades at $93.52, up 2.0% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth driven by Magic: The Gathering and digital gaming, though net income turned negative in 2025. Analyst consensus is a Buy with a $104.90 price target, supported by institutional accumulation and positive media coverage on franchise strength.

Outlook remains positive with 2026 revenue projected at $5.0B and net income of $794M, but risks include high debt levels, margin pressures from tariffs, and cybersecurity concerns. The stock offers a 2.93% dividend yield, with upside potential if growth sustains, yet volatility may persist amid cost headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Hasbro, Inc.

Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.

Read more on HAS